Gland Pharma Limited Asset Resilience Ratio
Gland Pharma Limited asset resilience ratio. Gland Pharma Limited (GLAND) has an Asset Resilience Ratio of 0.59% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Gland Pharma Limited (GLAND) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Gland Pharma Limited (2018–2026)
Asset resilience ratio of Gland Pharma Limited from 2018 to 2026. This chart shows how Gland Pharma Limited's Asset Resilience Ratio has changed over time. Read Gland Pharma Limited (GLAND) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Gland Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Gland Pharma Limited (GLAND) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs737.41 Million | 0.59% |
| Total Liquid Assets | Rs737.41 Million | 0.59% |
Asset Resilience Insights
- Limited Liquidity: Gland Pharma Limited maintains only 0.59% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Gland Pharma Limited Industry Peers by Asset Resilience Ratio
Compare Gland Pharma Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Gland Pharma Limited Asset Resilience Ratio by Year (2018–2026)
Gland Pharma Limited asset resilience ratio by year from 2018 to 2026. The table below shows the annual Asset Resilience Ratio data for Gland Pharma Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 0.59% | Rs737.41 Million ≈ $7.97 Million |
Rs125.11 Billion ≈ $1.35 Billion |
-2.94pp |
| 2025-03-31 | 3.53% | Rs3.96 Billion ≈ $42.83 Million |
Rs112.25 Billion ≈ $1.21 Billion |
-11.31pp |
| 2024-03-31 | 14.84% | Rs15.82 Billion ≈ $171.05 Million |
Rs106.61 Billion ≈ $1.15 Billion |
-6.29pp |
| 2023-03-31 | 21.12% | Rs18.54 Billion ≈ $200.50 Million |
Rs87.78 Billion ≈ $949.26 Million |
-16.24pp |
| 2022-03-31 | 37.36% | Rs29.27 Billion ≈ $316.53 Million |
Rs78.34 Billion ≈ $847.18 Million |
-1.29pp |
| 2021-03-31 | 38.65% | Rs25.11 Billion ≈ $271.52 Million |
Rs64.96 Billion ≈ $702.53 Million |
+10.68pp |
| 2020-03-31 | 27.97% | Rs11.43 Billion ≈ $123.58 Million |
Rs40.86 Billion ≈ $441.89 Million |
+14.22pp |
| 2019-03-31 | 13.75% | Rs4.84 Billion ≈ $52.38 Million |
Rs35.24 Billion ≈ $381.06 Million |
+4.25pp |
| 2018-03-31 | 9.50% | Rs2.78 Billion ≈ $30.10 Million |
Rs29.29 Billion ≈ $316.81 Million |
-- |
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The … Read more